BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Malaria readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Malaria\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07811908-11260@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Cipargamin: Phase 2 readout est. (NCT07811908)
DESCRIPTION:Cipargamin\, phase 2\, Malaria.\nStudy: Platform Study to Evalu
 ate the Efficacy and Safety of Anti-malarial Agents in Participants With U
 ncomplicated Plasmodium Falciparum Malaria (Cohort C2)\nEstimated primary 
 completion: 4 February 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cipargamin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07811908
URL:https://assetmemo.bio/drug/cipargamin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811908-11261@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Ganaplacide/lumefantrine: Phase 2 readout est. (NCT07811908)
DESCRIPTION:Ganaplacide/lumefantrine\, phase 2\, Malaria.\nStudy: Platform 
 Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Parti
 cipants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)\nEsti
 mated primary completion: 4 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ganaplacide-lumefantrine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07811908
URL:https://assetmemo.bio/drug/ganaplacide-lumefantrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545681-11207@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:GSK3772701: Phase 2 readout est. (NCT07545681)
DESCRIPTION:GSK3772701\, phase 2\, Malaria.\nStudy: A Phase 2A Study of a N
 ovel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. 
 Falciparum Malaria\nEstimated primary completion: 8 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/gsk3772701#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07545681
URL:https://assetmemo.bio/drug/gsk3772701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
